Company Overview of Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis...
1901 North Roselle Road
Schaumburg, IL 60195
Founded in 2006
Key Executives for Sagent Pharmaceuticals, Inc.
President, Chief Legal Officer and Corporate Secretary
Total Annual Compensation: $312.7K
Founder and Director
Total Annual Compensation: $615.2K
Chief Financial Officer and Executive Vice President
Total Annual Compensation: $330.8K
Executive Vice President of National Accounts & Corporate Development
Total Annual Compensation: $287.4K
Compensation as of Fiscal Year 2013.
Sagent Pharmaceuticals, Inc. Key Developments
Sagent Pharmaceuticals, Inc. Appoints Michael Logerfo as President
Apr 16 15
Sagent Pharmaceuticals, Inc. announced that its current EVP and Chief Legal Officer Michael Logerfo has been appointed President, effective April 15, 2015. In his new role as President, Mr. Logerfo will lead the company's Executive Management Committee, will continue to have primary responsibility over the company's strategic business development and legal functions, and will report to the Chairman of the Board. Mr. Logerfo has served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Sagent since March 2012.
Shlomo Yanai Joins Sagent Pharmaceuticals, Inc.'s Board of Directors
Apr 16 15
Sagent Pharmaceuticals, Inc. announced that Shlomo Yanai has been appointed to its Board of Directors effective April 15, 2015. Mr. Yanai served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 until 2012.
Sagent Pharmaceuticals, Inc. Announces the Launch of Vancomycin Hydrochloride for Injection, USP
Apr 13 15
Sagent Pharmaceuticals, Inc. announced the launch of Vancomycin Hydrochloride for Injection, USP, an anti-infective, in a 10 gram preservative-free pharmacy bulk package presentation. The Vancomycin 10 gram presentation is an addition to Sagent's Vancomycin 5 gram pharmacy bulk package offering. According to IMS, for the 12 months ending February 2015, the US market for Vancomycin approximated $196 million of which over 50% of the sales was pharmacy bulk package bottles. As with all products in Sagent's portfolio, Vancomycin features Sagent's PreventIV MeasuresS packaging and labeling, designed to help reduce medication errors.
Similar Private Companies By Industry
Recent Private Companies Transactions